# Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti

Source: https://onco.cc/trials/nct07291037/  
OnCo record `nct07291037` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Datopotamab deruxtecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.

## Summary

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations is a phase 3 interventional study registered as NCT07291037 by AstraZeneca, with 400 participants planned, started 2025-10-31 and due to reach its primary completion in 2029-01-29. Interventions recorded: Datopotamab deruxtecan (Dato-DXd), Docetaxel. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07291037
- Phase: 3
- Setting: A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
- Sponsor: AstraZeneca
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT07291037: https://clinicaltrials.gov/study/NCT07291037

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07291037.json